Researchers developed several new AI models that could guide the management of patients with non-valvular atrial fibrillation. There is still some work to do in terms of accuracy, but they already appear to outperform the traditional risk scores being used today.

A team of pediatric specialists worked closely with representative from Medtronic to develop the new pacemakers. Overall, the tiny devices—approximately one-quarter the size of a traditional pacemaker—were found to be both safe and effective. They are still under development.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

Kestra Medical Technologies, known for its wearable heart monitors and defibrillators, intends to sell 10 million common shares priced somewhere between $14 and $16 per share. 

These safety issues have been linked to more than 800 injuries and two deaths. It is possible, the FDA warned, that some patients may require a device to be removed and replaced. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

It can be challenging to know which AFib patients are the best candidates for LAAO. A new algorithm out of Mayo Clinic aims to address that problem.